Quest Diagnostics (NYSE:DGX) received a $108.00 target price from Mizuho in a report issued on Tuesday. The firm presently has a “buy” rating on the medical research company’s stock. Mizuho’s target price points to a potential upside of 15.87% from the company’s previous close.

A number of other analysts have also recently commented on DGX. Argus set a $120.00 target price on shares of Quest Diagnostics and gave the company a “buy” rating in a report on Friday, September 14th. Credit Suisse Group boosted their target price on shares of Quest Diagnostics from $121.00 to $128.00 and gave the company an “outperform” rating in a report on Monday, September 24th. Bank of America started coverage on shares of Quest Diagnostics in a report on Friday, October 19th. They set a “buy” rating on the stock. JPMorgan Chase & Co. dropped their target price on shares of Quest Diagnostics from $114.00 to $107.00 and set a “neutral” rating on the stock in a report on Wednesday, October 24th. Finally, Canaccord Genuity dropped their target price on shares of Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, October 24th. Eight analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Quest Diagnostics currently has an average rating of “Buy” and an average price target of $110.80.

Shares of DGX stock opened at $93.21 on Tuesday. Quest Diagnostics has a 12 month low of $90.54 and a 12 month high of $116.49. The firm has a market cap of $12.83 billion, a PE ratio of 17.26, a price-to-earnings-growth ratio of 1.70 and a beta of 0.90. The company has a current ratio of 1.15, a quick ratio of 1.09 and a debt-to-equity ratio of 0.63.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, October 23rd. The medical research company reported $1.68 EPS for the quarter, meeting the Zacks’ consensus estimate of $1.68. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter in the previous year, the business posted $1.38 EPS. The company’s quarterly revenue was up 1.8% on a year-over-year basis. As a group, analysts expect that Quest Diagnostics will post 6.56 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of DGX. Principal Financial Group Inc. raised its position in shares of Quest Diagnostics by 23.1% in the 1st quarter. Principal Financial Group Inc. now owns 436,117 shares of the medical research company’s stock worth $43,743,000 after purchasing an additional 81,936 shares during the last quarter. Xact Kapitalforvaltning AB raised its position in shares of Quest Diagnostics by 5.4% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 33,548 shares of the medical research company’s stock worth $3,688,000 after purchasing an additional 1,711 shares during the last quarter. Amalgamated Bank raised its position in shares of Quest Diagnostics by 2.7% in the 2nd quarter. Amalgamated Bank now owns 17,467 shares of the medical research company’s stock worth $1,920,000 after purchasing an additional 462 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Quest Diagnostics by 1.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 37,587 shares of the medical research company’s stock worth $4,132,000 after purchasing an additional 500 shares during the last quarter. Finally, Cornerstone Wealth Management LLC purchased a new position in shares of Quest Diagnostics in the 2nd quarter worth about $1,055,000. 86.00% of the stock is owned by hedge funds and other institutional investors.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Recommended Story: Quiet Period

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.